Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL
- 13 October 2019
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (3) , 315-323
Abstract
Aim: To examine the relationship between baseline fasting C‐peptide (FCP) and outcomes in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL (Gla‐100). Materials and methods: Post hoc pooled analysis of nine randomized, treat‐to‐target trials in patients with type 2 diabetes inadequately controlled on oral antihyperglycaemic drugs initiating once‐daily Gla‐100. Participants (n = 2165) were stratified at baseline according to FCP (≤0.40, >0.40–1.20, >1.20–2.00, >2.00 nmol/L). Glycaemic control, body weight, insulin dose and hypoglycaemia were determined at 24 weeks. Results: At baseline low FCP levels were associated with longer known diabetes duration, lower body mass index and higher fasting plasma glucose (FPG). Following Gla‐100 introduction, the mean HbA1c reduction at week 24 was similar in all four FCP groups, albeit fewer people in the lowest FCP group achieved HbA1c 0.40 nmol/L. By contrast, FPG reduction and proportion reaching FPG ≤5.6 mmol/L were greatest in the lowest FCP group, diminishing at higher FCP levels. Gla‐100 dose at week 24 was lowest in the ≤0.40 nmol/L FCP group and highest in the >1.20 nmol/L FCP group. Incidence and event rate of overall, nocturnal and severe hypoglycaemia were higher at week 24 in groups with lower FCP levels. In multivariable regression analysis baseline FCP, concomitant sulphonylurea use and endpoint HbA1c were strong predictors of hypoglycaemia. Conclusions: FCP levels identified patients with type 2 diabetes experiencing different responses to basal insulin Gla‐100. A low FCP identifies a markedly insulin‐deficient, insulin‐sensitive subgroup/phenotype with an enhanced risk of hypoglycaemia, which requires a low initial basal insulin dose, cautious titration and earlier addition of prandial glucose‐lowering therapy.Keywords
Funding Information
- Sanofi
This publication has 30 references indexed in Scilit:
- Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORDDiabetologia, 2015
- β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and TreatmentDiabetes Care, 2014
- The clinical utility of C‐peptide measurement in the care of patients with diabetesDiabetic Medicine, 2013
- C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-upEuropean Journal of Endocrinology, 2012
- Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their durationDiabetologia, 2007
- Frequency and predictors of hypoglycaemia in Type 1 and insulin‐treated Type 2 diabetes: a population‐based studyDiabetic Medicine, 2005
- The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitusDiabetologia, 2001
- Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions.Journal of Clinical Investigation, 1984
- C-Peptide Levels as a Criterion in Treatment of Maturity-Onset DiabetesThe Journal of Clinical Endocrinology & Metabolism, 1983
- Endogenous insulin secretion measured by C-peptide in maturity-onset diabetes controllable by diet aloneArchives of internal medicine (1960), 1981